Hydroxyapatite crystals as a bone graft substitute in benign lytic lesions of bone

被引:6
|
作者
Gupta, Anil Kumar [1 ]
Kumar, Praganesh [1 ]
Keshav, Kumar [1 ]
Singh, Anant [1 ]
机构
[1] GSVM Med Coll, Dept Orthopaed, Kanpur 208002, Uttar Pradesh, India
关键词
Benign lytic lesions of bone; bone graft substitute; hydroxyapatite crystals; GIANT-CELL TUMOR; PACKING;
D O I
10.4103/0019-5413.168767
中图分类号
R826.8 [整形外科学]; R782.2 [口腔颌面部整形外科学]; R726.2 [小儿整形外科学]; R62 [整形外科学(修复外科学)];
学科分类号
摘要
Background: Bone grafts are required to fill a cavity created after curettage of benign lytic lesions of the bone. To avoid the problems associated at donor site with autologous bone graft, we require allograft or bone graft substitutes. We evaluated the healing of lytic lesions after hydroxyapatite (HA) grafting by serial radiographs. Materials and Methods: Forty cases of benign lytic lesions of bone were managed by simple curettage and grafting using HA blocks. Commercially available HA of bovine origin (Surgiwear Ltd., Shahjahanpur, India) was used for this purpose. Mean duration of followup was 34.8 months (range 12-84 months). Mean patient age was 19.05 years (range 3-55 years). Radiological staging of graft incorporation was done as per criteria of Irwin et al. 2001. Results: In our series, two cases were in stage I. A total of 11 cases were in stage II and 27 were in stage III. Graft incorporation was radiologically complete by 15 months. Clinical recovery was observed before radiological healing. The average time taken to return to preoperative function was 3 months. Recurrence was observed in giant cell tumor (n = 3) and chondromyxoid fibroma (n = 1). There was no incidence of graft rejection, collapse, growth plate disturbances or antigenic response. Conclusions: We conclude that calcium HA is biologically acceptable bone graft substitute in the management of benign lytic lesions of bone.
引用
收藏
页码:649 / 655
页数:7
相关论文
共 50 条